Why Alexion Pharmacteuicals Sank 8.9% in November
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a commercial-stage biotech focused on rare diseases, fell 9% in November, according to data from S&P Global Market Intelligence. There doesn't appear to be any company-specific news that can explain the decline. Instead, it's likely that the pessimism from October simply carried over.
Image source: Getty Images.
While it was mostly a quiet month for the biotech, a few key news items were released during the period:
Source: Fool.com
